Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 155-161

  Witte, Larry ^a   Hicklin, Daniel J ^a   Zhu, Zhenping ^a   Pytowski, Bronislaw ^a   Kotanides, Helen ^a   Rockwell, Patricia ^b   Böhlen, Peter ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Angiogenesis; KDR; Monoclonal antibody; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, MITOGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0031870832     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006094117427     Document Type: Review

References (21)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995
2. Gradishar W: An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs 15: 49-59, 1997
3. Dvorak HF, Detmar M, Claffey KP, Nagy JA, Vandewater L, Senger DR: Vascular permeability factor vascular endothelial growth factor - an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107: 233-235, 1995
4. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1945
5. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992
6. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996
7. Zhang HT, Craft P, Scott PAE, Ziche M, Weich HA, Harris AL, Bicknell R: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Nat Cancer Inst 87: 213-219, 1995
8. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993
9. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in viro by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393-401, 1996
10. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461, 1995
11. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood island development and vasculogenesis in flk-1-deficient mice. Nature 376: 62-66, 1995
12. Lindner V, Reidy MA: Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler Thromb Vasc Biol 16: 1399-1405, 1996
13. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis. Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994
14. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996
15. Rockwell P, Goldstein N: Role of protein tyrosine kinase receptors in cancer: Possibilities for therapeutic intervention. Mol Cell Diff 3: 315-335, 1995
16. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3: 1222-1227, 1997
17. Rockwell P, Neufeld G, Glassman A, Caron D, Goldstein N: In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Mol Cell Diff 3: 91-109, 1995
18. Flanagan JG, Leder P: The kit ligand: A cell surface molecule altered in steel mutant fibroblasts. Cell 63: 185-194, 1990
19. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H: Different signal transduction properties of KDR and flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994
20. Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn D, Valyi-Nagy IT, Herlyn M: Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 143: 528-537, 1993
21. McLeod DS, Crone SN, Lutty GA: Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 37: 1322-1333, 1996